PhocusWright Conference Honors Magicstay.Com With Launch People's Choice Award
26.11.2019 16:28:00 EET | Business Wire | Press release
On Thursday, November 21, MagicStay won the Launch People's Choice Award at the Phocuswright Conference in Fort Lauderdale, Florida - the world's leading event showcasing the latest technological trends in tourism.
This prestigious award, a veritable acknowledgement of the entire tourism and mobility sector, is a reflection of MagicStay's development strategy, which was put into effect over the past two years on a global scale. With this award, MagicStay has established itself as a key player in Business Travel and mobility on the international stage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005486/en/
A special prize for a special team! #MagicTeam (Photo: Business Wire)
MagicStay, winner of the Launch People's Choice Award
The Launch People's Choice Award recognizes companies which are at least 4 years old and have come up with an innovation that revolutionizes the travel industry. Through this award, the Phocuswright Conference showcases the latest trends and technological innovations in the main sectors of the travel market every year.
In a 10-minute pitch, William Lecerf, co-founder of MagicStay, was able to impress the Dragons - the ten members of the Jury. He received nine positive endorsements in front of around 2,000 of the most influential international experts from the travel industry. The prize was presented to William Lecerf, co-founder (on the left), Valéry Linyer, co-founder and CEO (in the center) and Slobodan Petrovic, COO (on the right).
These 2,000 experts then elected MagicStay.com ahead of twelve competitors previously selected by Phocuswright: Affirm, Airdna, Amadeus, Arrivalist, Cover Genius, HotelRunner, Left Travel, Mistifly, Nezasa, Sift, Kiwi or Travelcompsitor. The prize was awarded jointly to MagicStay.com and Kiwi.
The Dragons' comments were very complimentary:
"You are building a database which offers unique value that no-one else has managed to develop".
Will Philippson,
former Co-founder and COO SilveRail Technologies
"I really like the fact that your content is available in the SBTs".
Charuta Fadnis,
Senior Director Product Strategy and Analytics BCD Travel
"As an expat looking for accommodation in a foreign country, anything you can do to simplify this process is absolutely fantastic. It's an infernal procedure that companies spend a lot of time dealing with and your solution is BRILLANT".
Philip Wolf,
Serial Board Director and Founder Phocuswright Inc.
"I was really impressed by your Duty of Care presentation. As a large company, I know that this issue is one of the biggest fears we have to face when sending our employees abroad on assignments".
Gayle Knolls,
Head of Business Development TRAVELPORT
An effective development strategy
Launched in 2013 in Grasse, the www.MagicStay.com platform devoted its first five years of business to R&D.
After initially focusing on the market of trade show organizers, since 2016 MagicStay has been offering business travelers and, since the beginning of this year, expatriates and/or persons on professional mobility assignments, a secure alternative to professional hotels by responding to duty of care challenges, traveler safety demands and personal data protection, required by large companies.
While broadening its scope, the hosting platform dedicated to professionals has doubled its offer since the beginning of the year. It now has more than 600,000 apartments, villas or apart-hotels available throughout the world (in more than 3,000 cities and 130 countries).
In 2020, MagicStay hopes to reach one million hosting units.
The photo on the previous page and other photos are available on request
MagicStay media library (press releases, logo, photo gallery, etc.)
Join us on: Facebook Twitter LinkedIn
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005486/en/
Contact information
MagicStay press contacts:
Fabienne Frédal (AB3C)
Tel. +33 (0)1 53 30 74 07 - fabienne@ab3c.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom